Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development20221109220121

Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development

adminNovember 9, 20220 comments
  Orlando, FL, Nov. 09, 2022 — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”) today announced that ...
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors20220927185925

Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors

adminSeptember 27, 20220 comments
  ORLANDO, FL, Sept. 27, 2022 — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmac...
Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes20220825173318

Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes

adminAugust 25, 20220 comments
  ORLANDO, FL, Aug. 25, 2022 — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a pioneering pharmac...
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer20220804131900

Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer

adminAugust 4, 20220 comments
  ORLANDO, FL, Aug. 04, 2022 — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmace...
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer20220722162600

Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer

adminJuly 22, 20220 comments
  ORLANDO, FL, July 22, 2022 — Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), a specialty pharmac...
Immune Therapeutics, Inc. Announces Expansion of its Board of Directors20220603172600

Immune Therapeutics, Inc. Announces Expansion of its Board of Directors

adminJune 3, 20220 comments
  ORLANDO, Fla, June 03, 2022 — Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the development, co...